Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

NCT05323955 is registered in ClinicalTrials.gov with Carey Anders, M.D. as lead sponsor.

NCT NCT05323955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05323955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Lead sponsor
Carey Anders, M.D.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 23, 2023
Completion date
November 30, 2027
Enrollment
48 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, brain metastases, human epidermal growth factor 2 positive carcinoma of breast